| |
Wednesday, April 2, 2025 | 11:00 AM ET
Get expert strategies for validating robust, scalable immunogenicity assays to reduce costs and minimize rework from early trials to market.
Register now.
|
|
Today’s Big NewsApr 1, 2025 |
|
Tuesday, April 8, 2025 | 1pm ET / 10am PT Learn how AI-powered digital phenotyping and real-world data (RWD) help identify overlooked patient populations, bridge gaps between clinical guidelines and real-world treatment, and refine commercial strategies. Join experts to discover how AI-driven insights can optimize market positioning and ensure therapies reach the right patients. Register now!
|
|
| By Gabrielle Masson At least 63 biopharma layoff rounds were conducted in the first quarter of this year, with cell and gene biotechs accounting for nearly a third of those rounds. The cuts were accompanied by eight biotech closures as the sector faces deep uncertainty tied to recent geopolitical changes. |
|
|
|
By James Waldron After a year of stripping back its head count and pipeline, Carisma Therapeutics is winding down operations and laying off any staff “not deemed necessary to pursue strategic alternatives.” |
By Ben Adams It’s been an inauspicious start to the first quarter as many biotechs are forced to slash and burn. Inspirna is the latest victim of this trend, although it’s going one step further. |
Sponsored by Allucent Project Optimus is changing the landscape of oncology drug development by redefining dose optimization standards. Learn how sponsors can align with FDA expectations and implement more precise dose-finding strategies. Watch the full interview with Alex MacDonald now! |
|
Wednesday, April 9, 2025 | 10am ET / 7am PT Learn the key steps for successfully entering Japan’s pharmaceutical market. This webinar covers regulatory requirements, compliance strategies, supply chain best practices, and common challenges. Gain expert insights to navigate this high-potential market with confidence. Don’t miss out—register now to secure your spot!
|
|
By Gabrielle Masson Vence Bonham Jr., the highest ranking official at the National Human Genome Research Institute, has been put on administrative leave. |
By Nick Paul Taylor Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better than placebo in phase 2 when given to people with early, untreated symptoms. |
By Gabrielle Masson Christopher Corsico, M.D., has left GSK to become Sanofi’s global head of development, effective immediately. |
By Darren Incorvaia AIRNA, a transatlantic RNA editing biotech, is preparing to launch its lead asset into clinical trials with fuel from a $155 million series B fundraise. |
By James Waldron AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks at its highest dose, hitting the goal of a phase 2 trial in patients with a lipid disorder. |
By James Waldron With the CSF-1R inhibitor space heating up, Merck Group has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 million to secure the global license to the drug. |
By James Waldron Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program partnership. |
By Nick Paul Taylor Lundbeck has stopped development of a subcutaneous formulation of its migraine drug Lu AG09222. The Danish drugmaker switched its focus to intravenous delivery after seeing phase 2b data, delaying the completion of the trial in the process. |
By Darren Incorvaia Fungi-focused biotech LifeMine Therapeutics is slimming down its staff and consolidating its operations to dig into clinical development of its lead asset, LifeMine CEO Gregory Verdine, Ph.D., confirmed to Fierce Biotech. |
By Eric Sagonowsky Peter Marks, M.D., Ph.D., a target for RFK Jr. and allies, last week turned in his resignation as director of the FDA's Center for Biologics Evaluation and Research. Before that, FDA commissioner Marty Makary signed off on his ouster, according to Politico. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we hear from Nada Hanafi, co-founder of MedTech Color, about the importance of diversity in healthcare settings. |
|
|---|
|
|
|
| Wednesday, April 9, 2025 | 11am ET / 8am PTCopay programs are designed to make treatments more affordable, but too often, patients don’t know they exist or how to use them. That means financial assistance goes unused, medications go unfilled, and patients face unnecessary barriers to starting and staying on treatment. Join us to learn how to move beyond outdated, manual copay distribution methods. Register now. |
|
| Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperRead about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperDiscover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
| WhitepaperDevelop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
